I know you are discouraged, as I am. I'm not a pumper or a promoter. I've just discussed the results with several leading invasive cardiologists in the New Jersey and New York, who have been awaiting these results. The overwhelming consensus was that this will alter the standard of care. I think the fact that the study was done in conjunction with Abbott Labs...added significant credibility as well as a potential partner. VOLC has had very strong financial results, but look at what they are spending in sales and marketing...A LOT. If they can leverage a firm like ABBOTT, with a worldwide salesforce, shipments for IVUS can rise significantly and perhaps exponentially. The medical community takes time to change, but it will change.
Also, at $16.70, VOLC has almost $3.00 per share in cash, and 11% of the float is short. VOLC remains relatively undiscovered. The analysts who follow the stock are all small shops...if they start becoming bigger shops, watch out! This will happen. But VOLC stock will be in the mid $20's before this happens.
Also, Abbott might just buy them out, as it could be super accretive to earnings.